Evidence map›Paper›PMID 42467395›Full record

ArticleEndocrine pathology2026

Circulating Tumor DNA Analysis in Adrenocortical Carcinoma: A Retrospective Cohort Study.

Vania Balderrama-Brondani, Leonardo Marcal, Mohammad Jad Moussa, James P Long, Jeena Varghese, Steven G Waguespack, Camilo Jimenez, Paul H Graham, Sarah B Fisher, Nancy Perrier and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Vania Balderrama-BrondaniDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Unit 1601, 1515 Holcombe Blvd, Houston, TX, 77030, USA. vbalderrama@mdanderson.org.ORCID http://orcid.org/0000-0002-9327-9615
Leonardo MarcalDepartment of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mohammad Jad MoussaDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
James P LongDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jeena VargheseDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Unit 1601, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Steven G WaguespackDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Unit 1601, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Camilo JimenezDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Unit 1601, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Paul H GrahamDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sarah B FisherDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nancy PerrierDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Amishi Y ShahDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rahul ShethDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Miao ZhangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Matthew T CampbellDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mouhammed Amir HabraDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Unit 1601, 1515 Holcombe Blvd, Houston, TX, 77030, USA. mahabra@mdanderson.org.ORCID http://orcid.org/0000-0002-4148-9637

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Center for Clinical and Translational SciencesUM1TR004906 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Maria Eulalia Fernandez, LORNA H. MCNEILL · 2024 to 2026
$16.7M
National Cancer Institute and the National Center for Advancing Translational Sciences of the NIH CCSG P30CA016672-46 and CCTS UM1TR004906NCATS NIH HHS UM1 TR004906NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Adrenocortical carcinoma (ACC) is a rare malignancy with high recurrence rates. Circulating tumor DNA (ctDNA) is a minimally invasive, blood-based biomarker with multiple oncologic applications. The role of ctDNA in ACC care remains understudied. This retrospective, single-institution, study evaluated real-world use of ctDNA testing in patients with ACC and its correlation with imaging-based tumor burden. Patients with ACC (≥ 18 years) who underwent ctDNA testing via a clinically validated, personalized, tumor-informed assay (Signatera™, Natera) during their disease course were reviewed, and clinical data were obtained from the medical records. ctDNA results were tested for association with disease status and tumor burden determined by concurrent imaging and clinical evaluation. Twenty patients (55% male) were included; the median age at first ctDNA assessment was 58.3 years (range, 23.3-81.1). A total of 87 ctDNA tests were analyzed (median, 4 tests/patient; interquartile range [IQR], 1-6). The median ctDNA level was 1.27 mean tumor molecules/mL (IQR, 0.05-22.86). Detected ctDNA was strongly associated with evidence of disease (odds ratio, 74; 95% confidence interval, 9-3438). The ctDNA assay demonstrated high sensitivity (88%), specificity (91.7%), and overall accuracy (88.5%), with a positive post-test probability of 98% and a negative post-test probability of 45%. In addition, ctDNA levels were positively correlated with tumor burden (Spearman R = 0.844; p < 0.001). These findings support the potential value of ctDNA testing for disease monitoring in ACC and it may support a more personalized approach to this rare disease.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaBiomarkers, TumorCirculating Tumor DNAAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesYoung AdultBiomarkers, TumorCirculating Tumor DNAAdrenal cancerLiquid biopsyMinimal residual diseasePrognosisTumor DNA

Identifiers

PMID42467395
PMCPMC13379401

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.